Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 28.09.
Forward PE Ratio (28.09) = Close Price ($402.91) / Consensus Forward EPS ($14.57)
FORWARD PE RATIO
28.09
SECTOR MEDIAN · HEALTHCARE
20.01
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
+40.38%
vs the sector median at left
Waters Corporation
Market Cap
$30.13B
Forward PE Ratio
28.09
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Waters Corporation (WAT) | $30.13B | 28.09 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $30.16B | 13.98 |
| Zoetis Inc. (ZTS)vs › | $30.86B | 12.12 |
| Medline Inc. (MDLN)vs › | $29.33B | 24.51 |
| Biogen Inc. (BIIB)vs › | $31.40B | 17.02 |
| DexCom, Inc. (DXCM)vs › | $31.90B | 32.95 |
| Centene Corp. (CNC)vs › | $31.90B | 13.45 |
| ResMed Inc. (RMD)vs › | $32.06B | 20.53 |
| Mettler-Toledo International Inc. (MTD)vs › | $26.79B | 28.42 |
| Labcorp Holdings Inc. (LH)vs › | $26.64B | 17.81 |
Trailing P/E
102.1
reported TTM EPS
Forward P/E
28.1
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $14.57 implies +263.3% EPS growth vs the reported trailing $4.01.
At today's $402.91 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $14.57 | $14.51 – $14.62 | 12 | 27.6x |
| 2027-12-31 | $16.50 | $16.03 – $17.75 | 13 | 24.4x |
| 2028-12-31 | $18.39 | $14.67 – $22.34 | 5 | 21.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
